Drug intelligence / Profile preview

V512

Development stage: Phase 1
Lead developer: Merck
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**V512** is Merck's investigational bivalent influenza peptide-conjugate vaccine, also termed BIPCV/IMX. It contains peptide antigens derived from influenza A matrix protein 2 and influenza B hemagglutinin precursor, formulated with a Merck aluminum adjuvant and the saponin-based ISCOMATRIX adjuvant. The vaccine was evaluated to induce immune responses and support prevention of influenza infection in healthy adults in a completed Phase 1 dose-escalation and dose-ranging study. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT00851266))

Other names: BIPCV/IMX

Targets

HA0 (Influenza B virus hemagglutinin)M2e (Influenza A matrix protein 2 ectodomain)

Beyond the preview

Go deeper on V512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V512.

Explore the full profile